
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$8.24
US$0.00 · 0.00%
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
前收盘价
US$8.24
US$0.00 · 0.00%
盘后
US$8.24
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
日内区间
当前US$8.24
52周区间
当前US$8.24
盘中时间采用ET。市场数据可能有所延迟。
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
日内区间
当前US$8.24
52周区间
当前US$8.24
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8655万 USD | 9413.5万 USD | 1.12亿 USD | 1.13亿 USD | 1.19亿 USD |
| 销货成本 | 4066.7万 USD | 3936.9万 USD | 4617.9万 USD | 5251.6万 USD | 5125.2万 USD |
| 毛利 | 4588.3万 USD | 5476.6万 USD | 6607.1万 USD | 6081.9万 USD | 6765.2万 USD |
| 研究与开发 | 882.5万 USD | 1040.6万 USD | 1176.4万 USD | 1232.9万 USD | 1079.9万 USD |
| 销售、一般及管理费用 | 3695.8万 USD | 4370.5万 USD | 4688.8万 USD | 4953.4万 USD | 4894.7万 USD |
| 营业费用 | 4651.2万 USD | 6097.7万 USD | 6417.7万 USD | 6775.2万 USD | 6558.6万 USD |
| 利息支出 | 491.7万 USD | 320.9万 USD | 359.1万 USD | 254.8万 USD | 154万 USD |
| 折旧和摊销 | 594.5万 USD | 715.7万 USD | 699.8万 USD | 757.5万 USD | 762.1万 USD |
| 营业利润 | −62.9万 USD | −621.1万 USD | 189.4万 USD | −693.3万 USD | 206.6万 USD |
| 净利润 | −5670万 USD | −1240.5万 USD | −341.5万 USD | −951.6万 USD | −28.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$38.00
上涨空间 361.17%价格历史记录不可用
最高:US$70.00平均的:US$38.00最低:US$6.00报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI100.13万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF34.1万0.00%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Sustainability Core 1 ETFDFSU1.57万0.00%23.92亿 USD0.15%US$48.13+0.04%
Dimensional - US Small Cap ETFDFAS1.34万0.00%338.69亿 USD0.31%US$78.17-0.23%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.01万0.00%61.81亿 USD0.26%US$68.32+0.06%
Dimensional - US Core Equity 2 ETFDFAC8478.960.00%885.96亿 USD0.21%US$45.31-0.04%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR7646.720.00%455.91亿 USD0.17%US$84.43-0.01%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Dimensional - US Sustainability Core 1 ETFDFSU
Dimensional - US Small Cap ETFDFAS
U.S. Vector Equity Portfolio ETF Class SharesDXUV
Dimensional - US Core Equity 2 ETFDFAC
U.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。